VERU: Rega marang dodolan Veru Pharma
Veru Inc. relies on high scalability upon FDA approval, where low capsule production costs combine with monopoly pricing. The company's average P/S confirms the market valuation, where 4.90 reflects the latest metric value. The process is accelerating through AI drug modeling, while the implementation of software robots for clinical test data analysis optimizes the time-to-market for medications.
Rincian analitis perusahaan Veru Pharma (VERU)
- rega saiki lan proyeksi nilai saham:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Rasio Kabeh Utang marang Dana Pribadi Veru Inc.|VERU - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal Veru Corporation|VERU - Utang perusahaan|Rasio utang marang nilai buku Veru Pharma|VERU - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Veru|Koefisien jangkoan perantara verupharma.com
- informasi bathi lan kelipatan valuasi:
VERU - Penghasilan resik|Bathi sing dikarepake Veru Inc.|VERU - Pangali P/E|Rasio prakiraan rega marang bathi Veru Inc|VERU - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Veru Pharma|VERU - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Veru|VERU - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan verupharma.com|VERU - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Veru Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis fundamental perusahaan:verupharma.com (VERU)
Veru Inc. development of oncology urology drugs and its close ties with clinics are reflected in the current P/S ratio dynamics. This metric compares market capitalization with annual sales volume to determine the cost of one dollar of revenue. The price-to-earnings ratio reveals the degree of asset overvaluation. Analyzing this coefficient allows an investor to assess the fairness of the pharmaceutical ecosystem's market value.
Perusahaan pesaing
Rasio rega marang pendapatan ONC (beigene.com)|Multiplikator P/S HALO (Halozyme)|Revolution Medicines Inc (RVMD) - Rega marang dodolan|AAPG - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CGON (CG Oncology Therapeutics)|URGN (UroGen Pharma Ltd.) - Kapitalisasi marang pendapatan|bicara.com (BCAX) - Multiplikator P/S|Kapitalisasi marang pendapatan PSNL|ERAS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DCTH|Koefisien rega marang pendapatan Y-mAbs Corp|Rasio rega marang pendapatan Aura Biosciences, Inc. AURA|CADL: Rasio kapitalisasi marang pendapatan|Accuray - Multiplikator P/S|SELLAS Life Sciences (SLS) - Kapitalisasi marang pendapatan|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|CTOR - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan HURA|Rasio rega marang pendapatan TARA|Multiplikator P/S FATE|WHWK - Rega marang dodolan|Rasio rega marang pendapatan TScan Therapeutics, Inc. TCRX|Rasio kapitalisasi pasar marang pendapatan CSBR|XBIT: Kapitalisasi marang pendapatan|CVM - Multiplikator P/S|OSTX: Multiplikator P/S|Kapitalisasi marang pendapatan radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator P/S|Multiplikator P/S Adlai Nortye Limited|Rasio rega marang pendapatan Tempest Therapeutics (TPST)|xiliotx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S RENB (Renovaro)|MURA - Kapitalisasi marang pendapatan|Kairos Pharma Inc - Multiplikator P/S|Rega marang dodolan OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Rasio rega marang pendapatan|Curis - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan APLM|THAR: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ADVB|Kapitalisasi marang pendapatan Genprex Inc GNPX|Calidi Biotherapeutics, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S sunshinebiopharma.com SBFM|XBIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SLRX (Salarius Pharmaceuticals Inc)|PPBT: Multiplikator P/S|Rega marang dodolan American Oncology Network, Inc. (AONC)|Kapitalisasi marang pendapatan BGNE|Rasio rega marang pendapatan CKPT|Multiplikator P/S ELEV|ICAD - Rega marang dodolan|Rasio rega marang pendapatan Ikena Oncology IKNA|Rasio kapitalisasi pasar marang pendapatan NTBL|VIRX: Kapitalisasi marang pendapatan|MOR - Multiplikator P/S|NAYA (NAYA Biosciences Inc.) - Kapitalisasi marang pendapatan|Ascentage Pharma Group International - Rasio kapitalisasi pasar marang pendapatan
